It’s the latest step from pharmacy benefit managers to respond to relentless criticism from politicians and regulators over ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...
Excerpts from recent editorials in the United States and abroad: ___ Jan. 26 The Washington Post on Trump's “energy emergency” Oil and gas production in the United States is hitting record highs, ...
At least one Woodward pharmacist is celebrating an action by Oklahoma Attorney General Gentner Drummond that could turn the ...
As the 119th Congress convenes, policymakers have a historic opportunity to lower prescription drug prices for Americans. As ...
The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...
Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems associated with generic HIV PrEP drug markups and potential ways to fix it.
Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...
Number 2: Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar competition, according to Samsung Bioepis’ most recent market report, ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Sen. Elizabeth Warren (D-Mass.) sent tech billionaire Elon Musk 30 ideas for how the newly formed Department of Government ...